Skip to main content
SpringerLink
Log in

Diffuse Large B-Cell Lymphomas in Older Adults

  • Living reference work entry
  • First Online:
Geriatric Oncology

  • 156 Accesses

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the elderly and is increasing in incidence. Although significant therapeutic advances have recently been made in the care of older DLBCL patients, based upon results of randomized clinical trials, many older patients are not eligible for such trials due to comorbidities and functional decline. Pretreatment evaluation of older patients to ascertain potential tolerance to therapy is especially important in therapeutic decisions for this population. Evaluation by performance status alone is insufficient, especially in the elderly, and consideration of the impact of comorbidities and functional/social decline needs to be included in such assessment. In this chapter, we will review approaches to therapy of the older patients with DLBCL, including initial treatment, role of maintenance therapy, use of combined modality therapy for limited stage disease, and strategies for the relapsed/refractory older patient. We will also address the issues of prognosis, comorbidities, geriatric assessment, supportive care measures in older patients with DLBCL, and recommendations for assessment and allied care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aaldriks AA, Giltay EL, Nortier JWR, et al. Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2015;56:927–35.

    Article  PubMed  Google Scholar 

  • Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–53.

    Article  CAS  PubMed  Google Scholar 

  • Aapro M, Bernard-Marty C, Brain E, Batist G, Erdkamp F, Krzemieniecki K, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22:257–67.

    Article  CAS  PubMed  Google Scholar 

  • Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphoma. Blood. 2000;96:1921–5.

    CAS  PubMed  Google Scholar 

  • Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151:143–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.

    Article  CAS  PubMed  Google Scholar 

  • Andorsky DJ, Cohen M, Naeim A, et al. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 2011;46:1219–25.

    Article  CAS  PubMed  Google Scholar 

  • Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77.

    Article  PubMed  Google Scholar 

  • Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984;32:269–73.

    Article  CAS  PubMed  Google Scholar 

  • Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.

    Article  CAS  PubMed  Google Scholar 

  • Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21:897–906.

    Article  PubMed  Google Scholar 

  • Aviles A, Cleto S, Huerta-Guzman J, Neri N. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP±BLEO regimens. Eur J Haematol. 2001;66:94–9.

    Article  CAS  PubMed  Google Scholar 

  • Avilés A, Neri N, Nambo J, et al. Maintenance therapy with interferon-a 2b, cyclophosphamide, and prednisone in aggressive diffuse large cell lymphoma. Stem Cells Dev. 2004;13:205–9.

    Article  PubMed  Google Scholar 

  • Balducci L. Aging, frailty, and chemotherapy. Cancer Control. 2007;14:7–12.

    Article  PubMed  Google Scholar 

  • Balducci L. Supportive care in elderly cancer patients. Curr Opin Oncol. 2009;21:310–7.

    Article  PubMed  Google Scholar 

  • Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000;35:147–54.

    Article  CAS  PubMed  Google Scholar 

  • Balducci L, Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer. 2004;100:6–11.

    Article  PubMed  Google Scholar 

  • Ballester OF, Moscinski L, Spiers A, Balducci L. Non-Hodgkin's lymphoma in the older person: a review. J Am Geriatr Soc. 1993;41:1245–54.

    Article  CAS  PubMed  Google Scholar 

  • Ballonoff A, Rusthoven KE, Schwer A, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008;72:1465–71.

    Article  PubMed  Google Scholar 

  • Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood. 2004;104:2933–5.

    Article  CAS  PubMed  Google Scholar 

  • Bastion Y, Blay JY, Divine M. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945–53.

    Article  CAS  PubMed  Google Scholar 

  • Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113:3896–902.

    Article  CAS  PubMed  Google Scholar 

  • Bonnet C, Fillet G, Mournier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:787–92.

    Article  CAS  PubMed  Google Scholar 

  • Campbell C, Sawka C, Franssen E, Berinstein NL. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin’s lymphoma without G-CSF support. Leuk Lymphoma. 1999;35:119–27.

    Article  CAS  PubMed  Google Scholar 

  • Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. Cancer. 2012;118:4156–65.

    Article  PubMed  Google Scholar 

  • Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin’s lymphoma. Blood. 1990;76:1293–8.

    CAS  PubMed  Google Scholar 

  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.

    Article  CAS  PubMed  Google Scholar 

  • Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51.

    Article  CAS  PubMed  Google Scholar 

  • Chen MG, Prosnitz LR, Gonzalez-Serva A, et al. Results of radiotherapy in control of stage I and II non-Hodgkin’s lymphoma. Cancer. 1979;43:1245–54.

    Article  CAS  PubMed  Google Scholar 

  • Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.

    Article  PubMed  PubMed Central  Google Scholar 

  • Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chrischilles EA, Klepser DG, Brooks JM, et al. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin’s lymphoma cases during first-course chemotherapy. Pharmacotherapy. 2005;25:668–75.

    Article  PubMed  Google Scholar 

  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  CAS  PubMed  Google Scholar 

  • Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008;112:2228–32.

    Article  CAS  PubMed  Google Scholar 

  • Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical eficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2014;14:343–55.

    Article  PubMed  Google Scholar 

  • Connors JM, O’Reilly SE. Treatment considerations in the elderly patient with lymphoma. Hematol Oncol Clin North Am. 1997;11:949–60.

    Article  CAS  PubMed  Google Scholar 

  • Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27:5573–9.

    Article  PubMed  Google Scholar 

  • Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol. 2009;64:907–16.

    Article  CAS  PubMed  Google Scholar 

  • Corrazelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy. Br J Haematol. 2011;154:579–89.

    Article  CAS  Google Scholar 

  • Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817–26.

    Article  CAS  PubMed  Google Scholar 

  • Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matsar MJ, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:2004–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood. 2010;116:4762–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525–33.

    Article  CAS  PubMed  Google Scholar 

  • Dorth JA, Prosnitz LR, Broadwater G, et al. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys. 2012;84:762–7.

    Article  PubMed  Google Scholar 

  • El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18:1363–8.

    Article  PubMed  Google Scholar 

  • Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10:192–6.

    Article  CAS  PubMed  Google Scholar 

  • Elstrom RL, Martin P, Hurtado Rua S, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87:433–5.

    Article  PubMed  Google Scholar 

  • Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the heart failure Association of the European Society of cardiology. Eur J Heart Fail. 2011;13:1–10.

    Article  PubMed  Google Scholar 

  • Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, et al. Hypoxia-inducible factor-1 (alpha) expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2010;28:1017–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Extermann M. Older patients, cognitive impairment, and cancer: an increasingly frequent triad. J Natl Compr Cancer Netw. 2005;3:593–6.

    Article  Google Scholar 

  • Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.

    Article  PubMed  Google Scholar 

  • Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.

    Article  CAS  PubMed  Google Scholar 

  • Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.

    Article  PubMed  Google Scholar 

  • Extermann M, Boler I, Reich R, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer. 2012;118:3377–86.

    Article  PubMed  Google Scholar 

  • Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.

    Article  CAS  PubMed  Google Scholar 

  • Fields FA, Townsend W, Webb A, et al. DeNovo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute project. J Clin Oncol. 2014;32:282–7.

    Article  CAS  PubMed  Google Scholar 

  • Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–6.

    Article  CAS  PubMed  Google Scholar 

  • Fontan L, Yang C, Kabaleeswaran V, et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012;22:812–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberagner W, Sihorsch K, Greil R. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. A randomized phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitgemeinschaft Medikamentose Tumortherapie AGMT] (NHL-14). Eur J Cancer. 2016;58:112–21.

    Article  CAS  PubMed  Google Scholar 

  • Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.

    Article  CAS  PubMed  Google Scholar 

  • Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505.

    PubMed  Google Scholar 

  • Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI. R-CHOP with iodine-131 tositumomab for advanced stage diffuse large B-cell lymphoma (DLBCL) : SWOG S0433. Br J Haematol. 2014;166:382–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gang AO, Pederson M, d’Amore F, Pederson LM, Jensen BA, Jensen P, Moller MB, Mourits-Anderson HT, Pederson RS, Klausen TW, Brown PDN. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from thr Danish Lymphoma Registry. Leuk Lymphoma. 2015;56:2556–62.

    Article  PubMed  CAS  Google Scholar 

  • Garcia-Suarez J, Flores E, Callejas M, Arribas I, Gil-Fernandez JJ, Olmedilla G, Curto N, Guillen H, Casco CR, Martin Y, Burgaleta C. Two-weekly dose-djusted (DA)-EPOCH-like chmeotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma. Br J Haematol. 2013;160:510–4.

    Article  CAS  PubMed  Google Scholar 

  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gisselbrecht C, Schmitz N, Mounier N, Singh GD, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Duhrsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Briere J, Salles G, Moskowitz CH, Glass B. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goede V, Schulz RJ. Geriatric assessment in older adults with aggressive lymphoma: growing evidence and new emerging questions. Leuk Lymphoma. 2015;56:835–6.

    Article  PubMed  Google Scholar 

  • Gomez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065–9.

    Article  CAS  PubMed  Google Scholar 

  • Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget sound oncology consortium. Leuk Lymphoma. 2010;51:1523–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol. 2010;148:235–44.

    Article  CAS  PubMed  Google Scholar 

  • Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264–9.

    Article  CAS  PubMed  Google Scholar 

  • Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.

    Article  CAS  PubMed  Google Scholar 

  • Hainsworth JD, Flinn IW, Spigel DR, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy:a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk. 2010;10:44–50.

    Article  CAS  PubMed  Google Scholar 

  • Haioun C, Mounier N, Emile JF, Ranta D, zCoiffier B, Tilly H, Recher C, Ferme C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20:1985–92.

    Article  CAS  PubMed  Google Scholar 

  • Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989–96.

    Article  CAS  PubMed  Google Scholar 

  • Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

    Article  CAS  PubMed  Google Scholar 

  • Hara T, Tsurumi H, Goto N, et al. Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. J Cancer Res Clin Oncol. 2009;135:1421–8.

    Article  CAS  PubMed  Google Scholar 

  • Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.

    CAS  PubMed  Google Scholar 

  • Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U, Nilsson-Ehle H, Andersson PO. Improved outcome for the very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma. 2012;53:394–9.

    Article  CAS  PubMed  Google Scholar 

  • Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112–8.

    Article  PubMed  Google Scholar 

  • Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin’s lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26:1850–7.

    Article  PubMed  Google Scholar 

  • Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:3159–65.

    Article  CAS  PubMed  Google Scholar 

  • Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol. 2011;24:1046–54.

    Article  PubMed  Google Scholar 

  • Horn J, Kleber M, Hieke S, et al. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol. 2012;91:1579–86.

    Article  CAS  PubMed  Google Scholar 

  • Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253–63.

    Article  CAS  PubMed  Google Scholar 

  • Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032–8.

    Article  CAS  PubMed  Google Scholar 

  • Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

  • Huang BT, Zeng QC, Yu J, et al. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. J Cancer Res Clin Oncol. 2012;138:125–32.

    Article  CAS  PubMed  Google Scholar 

  • Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jacobson JO, Grossbard M, Schulman N, Neuberg D. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma: a dose-intensity analysis. Clin Lymphoma. 2000;1:211–7.

    Article  CAS  PubMed  Google Scholar 

  • Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Yehuda DB, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsaio LT, AU WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klinger A, Chott A, Fridrik MA, Greil R. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;100:955–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology. 2009;1:523–31.

    Article  Google Scholar 

  • Jais JP, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia. 2008;22:1917–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Huterman S, Verheij KD, Coebergh JW. A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of international prognostic index. Br J Haematol. 2005;129:597–606.

    Article  PubMed  Google Scholar 

  • Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European blood and marrow transplantation registry. Haematologica. 2008;93:1837–42.

    Article  PubMed  Google Scholar 

  • Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma – a Nordic lymphoma group study. Ann Hematol. 2004;83:414–9.

    Article  CAS  PubMed  Google Scholar 

  • Jung HA, Park S, Cho JH, Ko YH, Kim SJ, Kim WS. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP : results from a prospective cohort study. Ann Hematol. 2012;91:1747–56.

    Article  CAS  PubMed  Google Scholar 

  • Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very eldserly patients with diffuse large B-cell lymphoma: consortium for improving survival of lymphoma study (CISL). Eur J Haematol. 2014;94:504–10.

    Article  PubMed  CAS  Google Scholar 

  • Kaminski MS, Coleman CN, Colby TV, et al. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med. 1986;104:747–56.

    Article  CAS  PubMed  Google Scholar 

  • Kemeny MM. Surgery in older patients. Semin Oncol. 2004;31:175–84.

    Article  PubMed  Google Scholar 

  • Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–8.

    Article  CAS  PubMed  Google Scholar 

  • Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–66.

    Article  PubMed  Google Scholar 

  • Launay-Vacher V, Chatelut E, Lichtman SM, Wildiers H, Steer C, Aapro M, International Society of Geriatric Oncology. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol. 2007;18:1314–21.

    Article  CAS  PubMed  Google Scholar 

  • Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008;14:1323–33.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci. 2008a;105:13520–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008b;359:2313–23.

    Article  CAS  PubMed  Google Scholar 

  • Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol. 2006;3:86–93.

    Article  CAS  PubMed  Google Scholar 

  • Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.

    Article  PubMed  Google Scholar 

  • Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:262–9.

    Article  CAS  PubMed  Google Scholar 

  • Lim ST, Hee SW, Quek R, et al. Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology. Leuk Lymphoma. 2008;49:149–51.

    Article  PubMed  Google Scholar 

  • Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, Szabo Z, Jaeger U. Impact of age group on febrile neutropenia risk assessment nd management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk. 2012;12:297–305.

    Article  CAS  PubMed  Google Scholar 

  • Lunning MA, Armitage JO. Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable? Haematologica. 2015;100:853–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402–9.

    Article  PubMed  Google Scholar 

  • Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069–76.

    Article  CAS  PubMed  Google Scholar 

  • Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117:1917–27.

    Article  PubMed  Google Scholar 

  • Marcheselli L, Marcheselli R, Bari A, et al. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52:1867–72.

    Article  CAS  PubMed  Google Scholar 

  • Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. Haematologica. 2011;96:720–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011;96:1888–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291–5.

    Article  CAS  PubMed  Google Scholar 

  • McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxy-daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–93.

    Article  CAS  PubMed  Google Scholar 

  • Merli F, luminari S, Rossi G, mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari a FA, Gobbi PG, Liberati AM, Federico M. Cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone, and rituximab fir the initial treatment of elderly ‘fit’ patients with diffue large B-celll lymphoma : results from the ANZINTER3 trial of the Intergruppo IItaliano Linfomi. Leuk Lymphoma. 2012;53:581–8.

    Article  CAS  PubMed  Google Scholar 

  • Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrati A, Spins M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Botelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M. Outcome of elderly frail patients with diffuse large B-cell lymphoma prospectively identified by comprehensive geriatric assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2014;55:38–43.

    Article  PubMed  Google Scholar 

  • Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:2386–93.

    Article  CAS  PubMed  Google Scholar 

  • Mikhaeel NG. Is 70 the new 60? New international prognostic index with an older age cut-off for diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:2487–8.

    Article  PubMed  Google Scholar 

  • Miller TP. The limits of limited stage lymphoma. J Clin Oncol. 2004;22:2982–4.

    Article  PubMed  Google Scholar 

  • Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460–6.

    CAS  PubMed  Google Scholar 

  • Miller TP, Dahlberg S, Cassaday JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–6.

    Article  CAS  PubMed  Google Scholar 

  • Miller TP, LeBlanc M, Spier CM, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphoma: update of the Southwest Oncology Group (SWOG) randomized trial. Blood. 2001;98:724a. (Abstract)

    Article  Google Scholar 

  • Miller TP, Unger JM, Spier CM, et al. Effect of adding ibritumomab tiuxetan (zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313). Blood. 2008;112:11. (Abstract 3598)

    Article  Google Scholar 

  • Monfardini S, Aversa SM, Zoli V, et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non- Hodgkin's lymphomas. Ann Oncol. 2005;16:1352–8.

    Article  CAS  PubMed  Google Scholar 

  • Monnereau A, Troussard X, Belot A, Guizard AV, Woronoff AS, Bara S, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer. 2013;132:2378–87.

    Article  CAS  PubMed  Google Scholar 

  • Morrison VA, Hong F, Habermann TM, et al. R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients: long-term follow-up of intergroup E4494/C9793. Blood. 2010;116:260. (Abstract 589)

    Google Scholar 

  • Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman S. Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care. An International Society of Geriatric Oncology (SIOG) expert position paper. J Geriatr Oncol. 2015a;6:141–52.

    Article  PubMed  Google Scholar 

  • Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman S. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Ann Oncol. 2015b;26:1058–68.

    Article  CAS  PubMed  Google Scholar 

  • Morrison VA, Weller E, Habermann T, Li S, Fisher R, Cheson B, Peterson B. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9792; ECOG/SWOG 4494). Leuk Lymphoma. 2017;58:1814.

    Article  CAS  PubMed  Google Scholar 

  • Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 – associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279–84.

    Article  CAS  PubMed  Google Scholar 

  • Mounier N, Canals C, Gisselbrecht C, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2012;18:788–93.

    Article  PubMed  Google Scholar 

  • Mudie NY, Swerdlow AJ, Higgins CD, et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British cohort study. J Clin Oncol. 2006;24:1568–74.

    Article  PubMed  Google Scholar 

  • Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hanel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trumper L, Rixecker T, Zwick C. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol. 2014;25:1800–6.

    Article  CAS  PubMed  Google Scholar 

  • Musolino A, Boggiani D, Panebianco M, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer. 2011;117:964–73.

    Article  CAS  PubMed  Google Scholar 

  • Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, et al. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol. 2012;156:196–204.

    Article  PubMed  Google Scholar 

  • Niitsu N, Umeda M. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin’s lymphoma. Am J Clin Oncol. 1997;20:311–4.

    Article  CAS  PubMed  Google Scholar 

  • Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2014;33:251–7.

    Article  PubMed  Google Scholar 

  • O’Connell JD, Harrington DP, Johnson GJ, Glick JH. Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol. 1986;4:1418.

    Article  PubMed  Google Scholar 

  • O’Reilly S, Connors JM, Macpherson N, et al. Malignant lymphomas in the elderly. Clin Geriatr Med. 1997;13:251–63.

    Article  PubMed  Google Scholar 

  • Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015;56:716–24.

    Article  CAS  PubMed  Google Scholar 

  • Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B. Frontline rituximab, cyclophoshamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126:1893–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:2103–9.

    Article  CAS  PubMed  Google Scholar 

  • Olszewski AJ, Mantripragada KC, Castillo JJ. Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma. J Natl Compr Cancer Netw. 2016;14:1121–9.

    Article  CAS  Google Scholar 

  • Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016;175:281–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258–63.

    Article  CAS  PubMed  Google Scholar 

  • Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–8.

    Article  CAS  PubMed  Google Scholar 

  • Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Oncol. 2017;4:e46–55.

    Google Scholar 

  • Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103–10.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly of 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. J Clin Oncol. 2004;104:634–41.

    CAS  Google Scholar 

  • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good- prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Schubert J, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Kuhnt E, Truemper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomized study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MHJ, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski M. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. J Clin Oncol. 2014a;32:4127–33.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Held G, Zeynalova S, et al. Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: results of the SEXIE-R-CHOP-14 trial of the DSHNHL. J Clin Oncol. 2014b;32:5s (Abstract 8501).

    Article  CAS  Google Scholar 

  • Phan J, Mazloom A, Medeiros JL, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170–6.

    Article  PubMed  Google Scholar 

  • Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, Garcia-Marco JA, Castellvi J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA group. Br J Haematol. 2015;169:188–98.

    Article  CAS  PubMed  Google Scholar 

  • Raimondi R, Tosetto A, Oneto R, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood. 2012;120:1327–33.

    Article  CAS  PubMed  Google Scholar 

  • Reddy S, Saxena VS, Pelletiere EV, et al. Early nodal and extra-nodal non-Hodgkin’s lymphomas. Cancer. 1977;40:98–104.

    Article  CAS  PubMed  Google Scholar 

  • Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197–205.

    Article  CAS  PubMed  Google Scholar 

  • Rigacci L, Fabbri A, Puccini B, et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)+/-rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer. 2010;116:4573–9.

    Article  CAS  PubMed  Google Scholar 

  • Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients : a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol. 2012;91:1013–22.

    Article  CAS  PubMed  Google Scholar 

  • Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010a;116:4045–59.

    Article  CAS  PubMed  Google Scholar 

  • Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010b;28:4996–5010.

    Article  PubMed  Google Scholar 

  • Rodriguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma. 2007;48:2172–8.

    Article  CAS  PubMed  Google Scholar 

  • Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  • Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, LaCasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesarman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2010;29:690–7.

    Article  PubMed  CAS  Google Scholar 

  • Sant M, Allemani C, De AR, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer. 2008;44:579–87.

    Article  PubMed  Google Scholar 

  • Sarif N, Joffe E, Gibstein L, Avivi I, Polliack A, Perry C, Herishanu Y, Reduced-dose ICE. Chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffue large B-cell lymphoma. Leuk Lymphoma. 2016;57:1633–9.

    Article  CAS  Google Scholar 

  • Sarkozy C, Coiffier B. Duffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res. 2013;19:1660–9.

    Article  CAS  PubMed  Google Scholar 

  • Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533–7.

    Article  CAS  PubMed  Google Scholar 

  • Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.

    Article  CAS  PubMed  Google Scholar 

  • Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.

    Article  CAS  PubMed  Google Scholar 

  • Sehn L, Savage K, Hoskins P, et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann Oncol. 2008;19:iv99. (Abstract 052)

    Article  Google Scholar 

  • Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197–204.

    Article  CAS  PubMed  Google Scholar 

  • Shikama N, Oguchi M, Isobe K, et al. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:217–22.

    Article  PubMed  Google Scholar 

  • Siegel AB, Lachs M, Coleman M, et al. Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymphoma Myeloma. 2006;7:65–9.

    Article  PubMed  Google Scholar 

  • Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.

    Article  CAS  PubMed  Google Scholar 

  • Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological malignancy research network. Br J Cancer. 2011;105:1684–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Solal-Celigny P, Chastang C, Herrera A, et al. Age as the main prognostic factor in adult aggressive non-Hodgkin’s lymphoma. Am J Med. 1987;83:1075–9.

    Article  CAS  PubMed  Google Scholar 

  • Sonnen R, Schmidt WP, Kuse R, et al. Treatment results of aggressive B-non-Hodgkin’s lymphoma in advanced age considering comorbidity. Br J Haematol. 2002;119:634–9.

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530–9.

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld P, Huijgens SP, Hagenbeek A. Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma. Ned Tijdschr Geneeskd. 1999;143:418–9.

    CAS  PubMed  Google Scholar 

  • Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Soubeyran P, Khaled H, MacKenzie M, et al. Diffuse large B-cell and peripheral T-cell non-Hodgkin’s lymphoma in the frail elderly: a phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment. J Geriatr Oncol. 2011;2:36–44.

    Article  Google Scholar 

  • Spicer J, Smith P, Maclennan K, et al. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin’s lymphoma. Br J Cancer. 2004;90:1151–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spina M, Balzarotti M, Uziel L, Ferreri AJM, Fratino L, Magagnoli M, Talamini R, Giacalone AA, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17:838–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34:2997–3004.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stopek AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for ptients with newly dignosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012;120:1210–7.

    Article  CAS  Google Scholar 

  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94.

    Google Scholar 

  • The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphoma. Summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112–35.

    Article  Google Scholar 

  • Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol. 2007;25:1916–23.

    Article  PubMed  Google Scholar 

  • Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. 2008;19:774–9.

    Article  CAS  PubMed  Google Scholar 

  • Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079–87.

    Article  PubMed  Google Scholar 

  • Tholstrup D, de Nully Brown P, Jurlander J, Hansen M. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2007;79:100–6.

    Article  CAS  PubMed  Google Scholar 

  • Tirelli U, Zagonel V, Serraino D, et al. Non-Hodgkin’s lymphomas in 137 patients aged 70 years or older: a retrospective European organization for research and treatment of cancer lymphoma group study. J Clin Oncol. 1988;6:1708–13.

    Article  CAS  PubMed  Google Scholar 

  • Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27–34.

    Article  CAS  PubMed  Google Scholar 

  • Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115:4547–53.

    Article  PubMed  Google Scholar 

  • Tucci A, Martelliu M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma. 2015;56:921–6.

    Article  CAS  PubMed  Google Scholar 

  • Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer. 2006;107:108–15.

    Article  PubMed  Google Scholar 

  • Vacirca J. Bendamustine combined with rituximab for relapsed or refractory diffuse large B-cell lymphoma. Blood 2009; 114 (Suppl 1). (Abstract 4750).

    Google Scholar 

  • Vaidya R, Witzig TE. Prognotic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol. 2014;25:2124–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer. 1994;69:1088–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vellenga E, van Putten WL, van’t Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111:537–43.

    Article  CAS  PubMed  Google Scholar 

  • Visani G, Ferrara F, Alesiani F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008;49:1081–6.

    Article  CAS  PubMed  Google Scholar 

  • Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15:730–7.

    Article  CAS  PubMed  Google Scholar 

  • Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1988;6:1838–44.

    Article  CAS  PubMed  Google Scholar 

  • Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–97.

    Article  CAS  PubMed  Google Scholar 

  • Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma. 2012;53:2290–2.

    Article  CAS  PubMed  Google Scholar 

  • Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–9.

    Article  CAS  PubMed  Google Scholar 

  • Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13:1285–9.

    Article  CAS  PubMed  Google Scholar 

  • Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839–44.

    Article  CAS  PubMed  Google Scholar 

  • Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–7.

    Article  PubMed  Google Scholar 

  • Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:840–6.

    Article  CAS  PubMed  Google Scholar 

  • Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48:1102–9.

    Article  CAS  PubMed  Google Scholar 

  • Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of utcome by molecular subtype. Haematologica. 2012;97:758–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wilson WH, Jung SH, Pitcher BN, et al. Phase II randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated large B-cell lymphoma: CALGB/alliance 50303. Blood. 2016;128(Suppl.) abstract 469

    Google Scholar 

  • Winkelmann N, Petersen I, Kiehntopf M, et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol. 2011;137:733–8.

    Article  PubMed  Google Scholar 

  • Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Kramer A, Ho AD. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicenter randomized phase III trial. Br J Haematol. 2015;171:710–9.

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27:5404–9.

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H, Kahl BS, Advani RH, Horning SJ. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell lymphoma: ECOG3402. Br J Haematol. 2015;170:679–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111–6.

    Article  CAS  PubMed  Google Scholar 

  • Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Lui W, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123–34.

    Article  CAS  PubMed  Google Scholar 

  • Yao YY, Tang Y, Zhu Q, et al. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma. 2013;54:1194–2000.

    Article  CAS  PubMed  Google Scholar 

  • Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemens P, Smit JW, Fourneau N, Oki Y. Combintion of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell on-Hodgkin lymphoma:a non-randomised, phase 1b study. Lancet Oncol. 2014;15:1019–26.

    Article  CAS  PubMed  Google Scholar 

  • Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Prfeundschuh M, et al. J Clin Oncol. 2010;28:2372–80.

    Article  CAS  Google Scholar 

  • Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, Derenzini E, Argnani L, Fina M, Tucci A, Botelli C, Pileri S, Baccarani M. Phase II trial of short course R-chop followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly difuse large B-cell lymphoma patients. Clin Cancer Res. 2010;16:3998–4004.

    Article  CAS  PubMed  Google Scholar 

  • Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11:462–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Minnesota, Minneapolis, MN, USA

    Vicki A. Morrison

  2. Hematology/Oncology, Hennepin County Medical Center, Minneapolis, MN, USA

    Vicki A. Morrison

Authors
  1. Vicki A. Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicki A. Morrison .

Editor information

Editors and Affiliations

  1. Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, Florida, USA

    Martine Extermann

Section Editor information

  1. Comprehensive Cancer Center of Wake Forest University, Winston-Salem, USA

    Heidi Klepin

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Morrison, V.A. (2018). Diffuse Large B-Cell Lymphomas in Older Adults. In: Extermann, M. (eds) Geriatric Oncology . Springer, Cham. https://doi.org/10.1007/978-3-319-44870-1_39-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44870-1_39-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44870-1

  • Online ISBN: 978-3-319-44870-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation